De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases
Authors:
- Jai RadhakrishnanJRJai Radhakrishnan
- David J. CohenDCDavid J. Cohen
- Leonard SternLSLeonard Stern
- Michael GoldsteinMGMichael Goldstein
- Mark HardyMHMark Hardy
- Vivette D. D'AgatiVDVivette D. D'Agati
- Glen S. MarkowitzGMGlen S. Markowitz
Open Access
- 1 January 2005
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (1) , 203-209
Abstract
The term thrombotic microangiopathy (TMA) has been applied to a diverse group of conditions that share the common pathomechanism of endothelial damage. TMA is a recognized complication of solid organ transplantation. The majority of cases represent de novo TMA, which occurs in ∼2.8–3.5% of renal transplant recipients and is associated with a 22% rate of graft loss [1]. The rate of graft loss is strongly influenced by whether the TMA is systemic or renal limited (38 vs 0% graft loss, respectively) [1].Keywords
This publication has 25 references indexed in Scilit:
- Thrombotic microangiopathy after renal transplantation in the United StatesAmerican Journal of Kidney Diseases, 2003
- Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study1 2Transplantation, 2003
- Sirolimus-induced thrombotic microangiopathy in a renal transplant recipientAmerican Journal of Kidney Diseases, 2003
- Delayed Graft Function and Cast Nephropathy Associated with Tacrolimus Plus Rapamycin UseJournal of the American Society of Nephrology, 2003
- Thrombotic Micro-Angiopathy with Sirolimus-Based Immunosuppression: Potentiation of Calcineurin-Inhibitor-Induced Endothelial Damage?American Journal of Transplantation, 2003
- Sirolimus May Promote Thrombotic MicroangiopathyAmerican Journal of Transplantation, 2003
- De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathyAmerican Journal of Kidney Diseases, 2003
- SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1Transplantation, 2001
- A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTSTransplantation, 2001
- TOR, a Central Controller of Cell GrowthCell, 2000